EIGR - Eiger BioPharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Eiger BioPharmaceuticals, Inc.

2155 Park Boulevard
Palo Alto, CA 94306
United States
650-272-6138
http://www.eigerbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Mr. David A. Cory R.Ph, MBABus. Founder, Pres, CEO & Director790.62kN/A1964
Dr. Jeffrey S. GlennFounder, Scientific Advisor & Director44.75kN/A1963
Mr. James P. Shaffer MBAChief Bus. Officer537.71kN/A1967
Dr. David ApelianDirector752.07kN/A1965
Mr. Sriram Ryali M.B.A.Chief Financial OfficerN/AN/A1981
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Corporate Governance

Eiger BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.